A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects With Ulcerative Colitis Who Completed the Study M11-290
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 24 Aug 2017 Planned End Date changed from 1 Jul 2023 to 28 Jul 2023.
- 24 Aug 2017 Planned primary completion date changed from 1 Jul 2020 to 19 May 2023.
- 23 Feb 2017 Planned End Date changed from 1 Jul 2020 to 1 Jul 2023.